21 results
PRE 14A
TYRA
Tyra Biosciences Inc
5 Apr 24
Preliminary proxy
4:20pm
retirement in June 2020, Mr. Fuhrman served as Chief Financial Officer of Amplyx Pharmaceuticals, Inc. Prior to Amplyx, Mr. Fuhrman served as Chief … of Compensation
Health and Welfare and Retirement Benefits; Perquisites
All of our current named executive officers are eligible to participate in our employee
8-K
EX-10.1
TYRA
Tyra Biosciences Inc
5 Feb 24
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
6:05am
Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (“ERISA”); no “reportable event
S-3
EX-4.4
5rsno
3 Oct 22
Shelf registration
4:05pm
S-3
EX-1.2
64nvd
3 Oct 22
Shelf registration
4:05pm
DEF 14A
merg5v5p8tonz bqaj
28 Apr 22
Definitive proxy
4:07pm
10-K
EX-10.15
jj7gdl0u
3 Mar 22
Annual report
4:31pm
8-K
EX-3.1
mwukiq 2mu
17 Sep 21
Amendments to Articles of Incorporation or Bylaws
4:01pm
424B4
zvvtr
15 Sep 21
Prospectus supplement with pricing info
4:10pm
S-1/A
EX-10.2
2n1xrvoybbp bj
9 Sep 21
IPO registration (amended)
6:08am
S-1/A
khrv01 jxltkf
9 Sep 21
IPO registration (amended)
6:08am
S-1
97g8 em7f9ki903
20 Aug 21
IPO registration
4:07pm
S-1
EX-10.19
xi6zi
20 Aug 21
IPO registration
4:07pm
S-1
EX-10.1
b16glkuhoriu332
20 Aug 21
IPO registration
4:07pm
S-1
EX-3.3
rk5u4uxft 48
20 Aug 21
IPO registration
4:07pm
DRS/A
89gl7f00m6upc 16t9
2 Jul 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.1
vsnwwzmtgryqz
2 Jul 21
Draft registration statement (amended)
12:00am